Keywords
Oncology hospital
Oncology
Tertiary treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objectives: To analyze cases in which the use of antibiotics is most appropriate for cancer patients; to identify and discuss the main types of drugs used; and to identify the best strategies for optimizing the use of antibiotics in order to increase patient safety. Methods: Observational and cross-sectional study of cancer patients. Microbial analysis was performed in partnership with the hospital's infectious disease team, analyzing cultures. The population consisted of all patients who presented positive cultures for bacteria. Sampling was performed for convenience, according to the culture results. Results: The results of this study demonstrated statistically significant associations (p<0.05) with resistance to the drugs Sulfamethazole + Trimethoprim (SUT), Piperacillin-tazobactam (PTZ), Gentamicin (GT), Ceftazidime (CAZ) related to patient outcomes. Regarding the overall outcome of the patients, 93 patients (73.2%) were discharged from hospital and 34 patients (26.8%) died. The most common malignant neoplasm in this study was colon cancer (15.7%), followed by prostate cancer (15%) and then Hodgkin's lymphoma (12.6%). Conclusion: Merely prescribing, without adequate justification, can lead to greater suffering for the patient, without cure control and inadequate management.
References
AVERBUCH D, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica, 2013; 98(12).
AVORN J e SOLOMON DH. Cultural and Economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Annals of Internal Medicine, 2000; 133(2): 128-135.
AZEVEDO MEF. Identificação de Enterococcus spp. e Avaliação da ocorrência de genes de resistência à vancomicina em amostras de pacientes de hospitais de Manaus, AM. Tese (Doutorado em Fisiopatologia em Clínica Médica) - Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Programa de Pós-Graduação em Fisiopatologia em Clínica Médica, Botucatu, 2013.
BAPTISTA MGFM. Mecanismos de Resistência aos Antibióticos. Dissertação (Mestrado Integrado em Ciências Farmacêuticas) - Faculdade de Ciências e Tecnologias da Saúde, Universidade Lusófona de Humanidades e Tecnologias, Lisboa, 2013.
BRASIL. MINISTÉRIO DA SAÚDE. Portaria. No 2616, 12 de maio de 1998.
BROOM J, et al. Why is optimisation of antimicrobial use difficult at the end of life? Internal Medicine Journal, 2019; 49(2): 269-271.
BUCANEVE G, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J. Clin. Oncol., 2014; 32: 1463-1471.
FREIFELD AG, et al. Clinical practice guideline for the use of antimicrobial agent sin neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis, 2011; 52: 5693.
FUCHS FD. Princípios Gerais de uso de antimicrobianos. In: Fuchs F, Wannamacher L, Ferreira M, editors. Farmacologia Clínica - Fundamentos da Terapêutica Racional. Rio de Janeiro, 2004: Guanabara Koogan; 2004; 3: 342.
GUIMARÃES DO, et al. Antibióticos: importância terapêutica e perspectivas para a descoberta e desenvolvimento de novos agentes. Quim. Nova, 2010; 33(3): 667-679.
IPAC. INFECTION PREVENTION AND CONTROL. Canada. Program Standard. Can J Infect Control. 2016; 30: 1-97.
LEE SF. Antibiotics in palliative care: less can be more. Recognising overuse is easy. The real challenge is judicious prescribing. BMJ Support Palliat Care, 2018; 8(2): 187-188.
NAUROIS J, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann. Oncol, 2010; 21: 252-256.
PEREIRA NML, et al. Manejo e Prevenção de Reações Adversas da Quimioterapia Antineoplásica com Platinas em Pacientes com Cânceres Esofágico e Gástrico: Revisão Sistemática da Literatura. Rev Bras Cancerol, 2021.
RIBEIRO-SANTOS G. Quimioterapia do Câncer: Imunossupressão x Imunoestimulação, 2025; 2(3).
SANTOS CDSM. Visão de futuro para produção de antibióticos: tendências de pesquisa, desenvolvimento e inovação. Tese (Doutorado em Ciências) - Escola de Química, Universidade Federal do Rio de Janeiro, Programa de Pós-Graduação em Tecnologia de Processos Químicos e Bioquímicos, Rio de Janeiro, 2014.
SANTOS MDO, et al. Estimativa de Incidência de Câncer no Brasil, 2023- 2025. Rev Bras Cancerol, 2023 [citado 25 de fevereiro de 2025]; 69(1).
SAWADA NO, et al. Avaliação da qualidade de vida de pacientes com câncer submetidos à quimioterapia. Rev. Esc. Enferm. USP, 2009; 43(3): 581–7.
STORR J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrob Resist Infect Control, 2017.
TORTORA GJ, et al. Microbiologia. Riode Janeiro, Artmed, 2012; 10.
TUMBARELLO M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J. Antimicrob. Chemother, 2015; 70: 2133-2143.
WHO. WORLD HEALTH ORGANIZATION. Guidelines on Core Components of Infection Prevention and Control Programmes at the National and Acute Health Care Facility Level. World Health Organization, 2016.